Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Sage (NASDAQ: SAGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus Pharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of Sage will receive $8.50 per share in cash (or an aggregate of ap